Day: April 8, 2024

OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024

OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024

LONDON and NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) — OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, announces that it will be rescheduling a Key Opinion Leader (KOL) event entitled “KOL Event Presenting Comprehensive Detailed Results from the Phase 2 Trial of OK-101 in Dry Eye Disease” originally planned for April 9th, 2024 at 12:00 PM ET until May 2024. The Company is rescheduling its event so that it can incorporate additional key analyses of its clinical data which it plans to present at upcoming ophthalmic conferences. OKYO...

Continue reading

<div>GFG Extends Private Placement & Plans to Close Financing on or Before April 19, 2024</div>

GFG Extends Private Placement & Plans to Close Financing on or Before April 19, 2024

NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRES SASKATOON, Saskatchewan, April 08, 2024 (GLOBE NEWSWIRE) — Canada: GFG Resources Inc. (TSXV: GFG) (OTCQB: GFGSF) (“GFG” or the “Company”) announces that the Company has received approval from the TSX Venture Exchange to extend the closing of its previously announced non-brokered private placement financing (the “Offering”) (see news release dated February 22, 2024). The Company anticipates closing the financing on or before April 19, 2024. This news release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities, in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. The securities...

Continue reading

Vast announces Term Sheet to facilitate transmission access for Aurora Energy Precinct

Vast announces Term Sheet to facilitate transmission access for Aurora Energy Precinct

SYDNEY, Australia, April 08, 2024 (GLOBE NEWSWIRE) — Vast Renewables Limited (Vast) (Nasdaq: VSTE) and 1414 Degrees Limited (ASX:14D), through their joint venture SiliconAurora Pty Ltd (SiliconAurora), today announced the signing of a term sheet (Term Sheet) with Vast Solar 1 Pty Ltd and OZ Minerals Services Pty Ltd (OZM), a subsidiary of BHP Group Limited (BHP), to enter into negotiations with OZM for a possible binding agreement (Agreement) by 30 September 2024 (which date can be extended by mutual consent) (Agreement Date) that would facilitate access for the initial stages of the Aurora Energy Precinct (the Precinct) to the ElectraNet owned Hill-to-Hill Transmission Line (H2H) near Port Augusta, South Australia. The Precinct is owned by SiliconAurora, which plans to develop a 140MW (2 hour) battery energy storage system (BESS)...

Continue reading

<div>Rio2 Announces Receipt of RCA Resolution for the Fenix Gold Project & C$10 Million Private Placement</div>

Rio2 Announces Receipt of RCA Resolution for the Fenix Gold Project & C$10 Million Private Placement

Not for distribution to United States Newswire Services or for dissemination in the United States VANCOUVER, British Columbia, April 08, 2024 (GLOBE NEWSWIRE) — Rio2 Limited (“Rio2” or the “Company”) (TSXV: RIO; OTCQX: RIOFF; BVL: RIO) today announces that its Chilean subsidiary, Fenix Gold Limitada (“Fenix Gold”), has received the formal Resolución de Calificación Ambiental (Environmental Qualification Resolution, or RCA) for its Fenix Gold Project (the “Project”) located in the Maricunga Mineral Belt of the Atacama Region, Chile. The RCA has been issued following the approval of the Project’s Environmental Impact Assessment previously announced on December 20, 2023. The receipt of the RCA now allows Fenix Gold to advance permitting activities for the Project. There are four principal Sectorial Permits required before construction...

Continue reading

Opthea Appoints John Han, PharmD, as VP Medical Affairs

Opthea Appoints John Han, PharmD, as VP Medical Affairs

Brings extensive experience in retinal and ophthalmology diseases MELBOURNE, Australia and PRINCETON, N.J., April 08, 2024 (GLOBE NEWSWIRE) — Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced the appointment of John Han, PharmD, to the role of Vice President, Medical Affairs, effective April 9, 2024. Dr. Han will report to Chief Executive Officer (CEO), Frederic Guerard, PharmD, and will join the Opthea Executive Management Team. Dr. Han brings over 20 years of experience building medical affairs programs and partnering across organizations to lead pre- and post-launch initiatives for medicines in ophthalmology and retinal...

Continue reading

Smith+Nephew signs exclusive distribution agreement to provide unique NAVBIT SPRINT™ solution in Australia

Smith+Nephew signs exclusive distribution agreement to provide unique NAVBIT SPRINT™ solution in Australia

Compact, single-use, and simple-to-use technology offers surgeons a fast, reliable navigation solution for hip arthroplasty Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, announced an agreement with NAVBIT to exclusively distribute the NAVBIT SPRINT™ in Australia during the recent Australian Orthopedics Association COE Meeting in Sydney. A single-use, sterile navigation system with everything provided in a small carton, NAVBIT SPRINT™ is designed to suit busy surgeons – and its convenient product format makes it extremely practical and cost efficient for hospitals and day surgery environments. This exclusive distribution builds upon the agreement Smith+Nephew announced for Japan in April 2023. Lynette Walter, NAVBIT’s CEO said, “We are absolutely delighted to expand our partnership with Smith+Nephew...

Continue reading

Churchill Downs Incorporated Closes on Sale of 49% of  United Tote Company to the New York Racing Association, Inc.

Churchill Downs Incorporated Closes on Sale of 49% of United Tote Company to the New York Racing Association, Inc.

LOUISVILLE, Ky., April 08, 2024 (GLOBE NEWSWIRE) — Churchill Downs Incorporated (Nasdaq: CHDN, “CDI,” or the “Company”) announced today that the Company closed on the sale of 49% of United Tote Company (“United Tote”), a wholly-owned subsidiary of CDI, to NYRA Content Management Solutions, LLC, a subsidiary of the New York Racing Association, Inc. (“NYRA”). About Churchill Downs Incorporated Churchill Downs Incorporated (“CDI”) (Nasdaq: CHDN) has been creating extraordinary entertainment experiences for nearly 150 years, beginning with the company’s most iconic and enduring asset, the Kentucky Derby. Headquartered in Louisville, Kentucky, CDI has expanded through the development of live and historical racing entertainment venues, the growth of the TwinSpires horse racing online wagering business and the operation and development...

Continue reading

Premier Health Announces the Appointment of Bruno Morel as its New CTO

Premier Health Announces the Appointment of Bruno Morel as its New CTO

MONTRÉAL, April 08, 2024 (GLOBE NEWSWIRE) — Premier Health of America Inc. (TSXV: PHA) (the “Corporation” or “Premier Health”), a leading Canadian Health tech company, announces the appointment of Bruno Morel as the Corporation’s new Chief Technology Officer, effective immediately. “We are very excited to have Bruno join Premier Health. His hiring follows our recent Canadian expansion and is one of the key catalysts of our technology roadmap. He will be an important member of the Corporation’s senior leadership team as we continue to expand and execute our growth strategy,” said Martin Legault, Chief Executive Officer. Bruno has over 20 years of experience building complex software and managing development and operation teams in fast developing technology companies. Over the years, he has developed an expertise in the definition...

Continue reading

Audited results of Invalda INVL Group for 2023

Audited results of Invalda INVL Group for 2023

Invalda INVL, which is the leading asset management group in the Baltics, had equity of EUR 178 million at the end of 2023, or EUR 14.83 per share. The figures were 36.1% and 34% larger, respectively, than a year earlier.  Invalda INVL had record earnings last year. Its audited net profit was EUR 45.82 million, or 2.7 times the 2022 profit of EUR 16.67 million.  “2023 was a successful and strategically important year for the Invalda INVL group. Sustained and focused efforts to build and grow the business with a favourable economic landscape across the target markets and sectors we invest in led to significant profits being returned to our investors and for the Group,” says Darius Šulnis, the CEO of Invalda INVL.  “While we take the current geopolitical situation extremely seriously, we are continuing with our efforts to the benefit of...

Continue reading

Sirios grants Brunswick right to purchase a royalty on select claims of the Mirage Property

Sirios grants Brunswick right to purchase a royalty on select claims of the Mirage Property

MONTREAL, April 08, 2024 (GLOBE NEWSWIRE) — The directors of Sirios Resources Inc. (TSX-V: SOI; OTCQB: SIREF) (“Sirios”) are pleased to announce that Sirios has signed an agreement with Brunswick Exploration Inc. (“Brunswick”) granting it the right to purchase a 0.5% Net Smelter Return (“NSR”) held by Sirios on 8 claims that are part of Brunswick Exploration’s Mirage lithium property located in Eeyou Istchee James Bay (ref. : 29/08/2023 Press Release). Under the terms of the purchase agreement, Brunswick shall: Make a cash payment of $50,000 within five business days of the agreement’s effective date; Pay installments in cash, shares or a combination of both subject to a minimum 25% in cash (share amount calculated based on 10-day Volume Weighted Average Share Price preceding the date of the payment and subject to a $0.40 minimum...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.